Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
Medical Product
|
| gptkbp:advantage |
Longer shelf life than blood
No blood type matching required No risk of infectious disease transmission |
| gptkbp:alsoKnownAs |
gptkb:Artificial_Blood
|
| gptkbp:approvedBy |
gptkb:Russia
gptkb:South_Africa |
| gptkbp:canBe |
gptkb:Jehovah's_Witnesses_patients
Disaster response Emergency medicine Remote locations Military medicine |
| gptkbp:compatibleWith |
gptkb:European_Union
gptkb:United_States Clotting function replacement Immune function replacement Long-term replacement of blood |
| gptkbp:component |
Hemoglobin
Perfluorocarbon Saline solution Starch solution |
| gptkbp:example |
gptkb:Fluosol-DA
gptkb:Hemopure gptkb:Oxycyte gptkb:Oxyglobin gptkb:PolyHeme |
| gptkbp:excludes |
Plasma proteins
Platelets White blood cells |
| https://www.w3.org/2000/01/rdf-schema#label |
Blood Substitute
|
| gptkbp:limitation |
Side effects
Limited oxygen-carrying capacity Not widely available |
| gptkbp:purpose |
Replace biological blood
|
| gptkbp:regulates |
Experimental in most countries
|
| gptkbp:researchedSince |
19th century
|
| gptkbp:riskFactor |
Allergic reactions
Organ toxicity Short half-life |
| gptkbp:storage |
Room temperature
Long shelf life |
| gptkbp:studiedBy |
Medical researchers
Biotechnology companies Pharmaceutical companies |
| gptkbp:type |
Hemoglobin-based oxygen carriers
Perfluorocarbon-based oxygen carriers Volume expanders |
| gptkbp:usedFor |
Blood transfusion
Oxygen transport Volume expansion |
| gptkbp:bfsParent |
gptkb:Margaret_Duffy
|
| gptkbp:bfsLayer |
6
|